Aaron Balog

Bristol Myers Squibb · company speakers →

discussed BMS-986449, a small molecule that selectively degrades transcription factors Helios (IKZF2) and Eos (IKZF4) to reprogram immunosuppressive regulatory T cells and promote effector activity.

Is this you? Claim this profile →

No public contact links on file.

Speaking history

AACR Drug Discovery and Development (AACR D3)

21 July 2026 Boston, United States “BMS-986449: Immunomodulatory Transcription Factor Degrader in Solid Cancers”

Sourcing speakers for your event?

Browse the speaker directory →